DesBio/Deseret Biologicals, Inc.
FDA issued a warning letter to DesBio/Deseret Biologicals, Inc. (Sandy, UT, United States) on Oct 1, 2026, citing 21 CFR 201.128. Subject: Unapproved New Drugs.
From the letter: “No approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, is in effect for this product.*1* Accordingly, this product is an unapproved new drug.”
At a glance
What a reviewer notes before reading: findings, citations, the response deadline and what the letter warns of.
- Violations
- 1 finding · 1 issue type
- Cited
- 21 CFR 201.128
- Response due
- Fifteen (15) business days of receipt
- FDA asks for
- 4 actions
- Named as possible actions
- Seizure, injunction
- Issued by
- Center for Drug Evaluation and Research
- Published status
- No close-out recorded
AI assisted findings
Model-assisted reading of each issue. Open one to see the FDA text it comes from, and check it against the full letter.
01Registration, listing & premarketThe product is an unapproved new drug marketed without an FDA-approved application.
No approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, is in effect for this product.*1* Accordingly, this product is an unapproved new drug.
What FDA requested
- Provide specific steps taken to correct the violations.
- Provide explanation of steps to prevent recurrence of violations.
- Provide copies of related documentation.
- Provide information demonstrating products are not in violation.
FDA Warning Letter
30 paragraphs · 5 sectionsText as published on FDA.gov, retrieved Nov 4, 2026. Layout added for reading; the wording is FDA’s. View on FDA.gov (opens in a new tab)
1Introduction
2 paragraphs
This warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) review of your website, https://desbio.com/, and provides you an opportunity to address them. Promptly address any violations described herein without delay, including ensuring that appropriate resources are allocated to fully address them and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction.
As discussed below, the “CHLA:10M” product available for purchase on your website is an unapproved new drug. Unapproved drug products marketed for the treatment of sexually transmitted infections (STIs) and/or their symptoms and sold directly to consumers present a serious public health concern. Individuals who rely on these products may forgo timely, appropriate medical care, increasing their risk of severe complications such as infertility, sepsis, and death. Further, a false sense of having been adequately treated may lead individuals to unknowingly transmit infections to their partners. FDA has not approved any over-the-counter (OTC) drug product for the treatment, cure, mitigation, or prevention of any STI. Effective treatment requires diagnosis and supervision by a licensed healthcare professional.
2FDA Review
2 paragraphs
Violations were identified and documented during a review of your website https://desbio.com/ in July 2026. Based on our review, “CHLA:10M” is an unapproved new drug under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering this product for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).
This review was conducted as part of FDA’s public health responsibility to protect the public from unsafe, ineffective, and poor-quality drugs.
3Violations of the Federal Food, Drug, and Cosmetic Act
1 paragraph
The following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations.
4Unapproved New Drug Violations
8 paragraphs
Based on a review of your website, “CHLA:10M” is a drug under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and/or intended to affect the structure or any function of the body. Examples from your product labeling, including on your website, that provide evidence of the intended use (as defined in 21 CFR 201.128) of this product as a drug include, but may not be limited to, the following:On the product label:
“Chlamydia 10M”
“Chlamydia trachomatis 10M . . . Burning Sensation During Urination, Testicular Tenderness or Pain, Vaginal Discharge, Painful Sexual Intercourse”
On the webpage https://desbio.com/product/chlamydia-series-symptom-relief-series-kit-10m/:
“chlamydia, series symptom relief”
“CHLA:10M is for the temporary relief of symptoms related to Chlamydia infection. Male: burning sensation during urination and testicular tenderness or pain. Female: vaginal discharge, burning sensation during urination, and painful sexual intercourse.”
“CHLA:10M” is a “new drug” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p), because it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, is in effect for this product.1 Accordingly, this product is an unapproved new drug.
The introduction or delivery for introduction into interstate commerce of this unapproved new drug product violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).
5Conclusion
3 paragraphs
As previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.
Send your written response to FDAAdvisory@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Include the specific steps you have taken to correct any violations, an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration. Identify your response with reference number “735464” in the subject line of the email.
Please note FDA posts warning letters on www.fda.gov.
Citations and trends
Each 21 CFR section, ISO 13485 clause and issue type in this letter, how often it appears across all letters, and its trend by the year FDA issued the letters. 2026 runs to Nov 10, 2026, compared with the same dates last year. Select a row or a bar to see those letters in Letters. As cited in this historical letter, not a statement of current requirements.
Regulations
Issue types
Record details
- Issuing center
- Center for Drug Evaluation and Research
- Issuing office
- Center for Drug Evaluation and Research
- Location
- Sandy, UT, United States
- Letter posted date
- Oct 6, 2026
- Letter issue date
- Oct 1, 2026
- Addressed to
- Chief Executive Officer
- Inspection dates
- Not recorded
- Response window
- 15 business days after receipt of this letter
Read the source clause
Send your written response to FDAAdvisory@fda.hhs.gov within fifteen (15) business days of receipt of this letter.
- Record length
- 1,082 words · 0 recorded redactions
- Published status
- No published close-out
- FDA reference
- 735464
- Original letter
- View on FDA.gov (opens in a new tab)
- Dataset last checked
- Nov 20, 2026 · How this is built
A response window is not a calculated due date. Source excerpts are selected passages. Finding interpretations and categories are model-assisted. Verify the original letter before relying on a finding.